34 completed, 5 unknown, 2 terminated, 2 withdrawn. 19 Phase 4, 9 Not applicable, 7 Phase 3, 5 Phase 1, 1 Phase 2.
Follow Gliclazide: new trials by email Literature Review of Gliclazide trials Research Report on Gliclazide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparative Study of Sitagliptin and Gliclazide With Metformin in Type 2 Diabetes Patients With Glucotoxicity Sitagliptin and Gliclazide, Metformin - Type 2 Diabetes Mellitus, Glucotoxicity | Phase 4 | Completed | Zhibin Xu | 129 | 2024-06-01 | 2024-09-26 |
| Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical Trial Henagliflozin, Gliclazide - Type 2 Diabetes Mellitus, Mild Cognitive Impairment | Not applicable | Completed | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 24 | 2024-04-01 | 2025-07-10 |
| Effect of Dorzagliatin on Renal Function Outcomes in People With Type 2 Diabetes: a Multicentric, Prospective, Randomized Study. Dorzagliatin, Gliclazide - Diabetic Nephropathy Type 2 | Not applicable | Unknown | Yan Bi | 106 | 2024-02-20 | 2024-01-24 |
| Study of Sulphonylurea Synergy With DPP4 Inhibitors Sulfonylurea, DPP4 Inhibitor - Type 2 Diabetes | Not applicable | Completed | University of Dundee | 30 | 2019-10-08 | 2021-03-04 |
| Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers Omeprazole, Placebo oral tablet, Gliclazide - Diabetes Mellitus, Type 2 | Phase 1 | Completed | University of Sarajevo | 15 | 2019-03-04 | 2021-08-18 |
| Study of Sulphonylurea Synergy With Incretins Gliclazide - Type 2 Diabetes Mellitus | Not applicable | Completed | University of Dundee | 20 | 2018-08-03 | 2020-02-24 |
| Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants Metformin/Gliclazide Fixed Combination, Metformin, Gliclazide - Healthy | Phase 1 | Completed | Merck KGaA, Darmstadt, Germany | 40 | 2018-02-16 | 2019-07-16 |
| Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES EMPA/LINA 10/5 mg QD (n=22), LINA/EMPA 5/10 mg QD (N=22), Gliclazide 30 mg QD/BID (N=22) - Type2 Diabetes | Phase 4 | Unknown | M.H.H. Kramer | 66 | 2017-11-09 | 2022-01-14 |
| Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients Cabergoline, Gliclazide - Diabetes | Phase 3 | Unknown | Sherief Abd-Elsalam | 60 | 2017-10-14 | 2018-08-27 |
| HbA1c Variability in Type II Diabetes Metformin, Gliclazide, Sitagliptin - Diabetes Mellitus Type 2 | Not applicable | Active not recruiting | Weill Cornell Medical College in Qatar | 150 | 2016-11-01 | 2025-07-20 |
| Effect of Anti-diabetic Drugs on Glycemic Variability Dapagliflozin, Gliclazide MR - Diabetes Mellitus, Type 2 | Phase 4 | Completed | Centro de Diabetes Curitiba Ltda | 135 | 2016-10-01 | 2020-03-04 |
| Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan Canagliflozin, Repaglinide, Pioglitazone - Diabetes Mellitus, Type 2 | Phase 4 | Completed | University of Leicester | 25 | 2016-07-01 | 2020-01-30 |
| Renoprotective Effects of Dapagliflozin in Type 2 Diabetes Dapagliflozin 10mg QD, Gliclazide 30mg QD - Diabetes Mellitus, Type 2, Diabetic Nephropathies | Phase 4 | Completed | M.H.H. Kramer | 44 | 2016-02-01 | 2020-07-07 |
| Clinical Bioequivalence Study on Two Gliclazide 80mg Tablet Formulations BF-Gliclazide Tablet 80mg, Diamicron 80mg Tablet - Healthy | Phase 1 | Completed | Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited | 17 | 2016-01-01 | 2016-07-25 |
| Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide Dapagliflozin, Gliclazide - Diabetes | Phase 4 | Completed | Seoul National University Bundang Hospital | 32 | 2015-11-01 | 2018-09-11 |
| Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study Gliclazide, Glibenclamide - Diabetes | Phase 4 | Completed | Khoo Teck Puat Hospital | 8 | 2014-08-01 | 2016-09-01 |
| Bioequivalence Study of Gliclazide 120 mg Modified Release Tablets Gliclazide 120 mg MR Tablets Formula A, Gliclazide 120 mg MR Tablets, Gliclazide 120 mg MR Tablets Formula B - Comparative Bioavailability | Phase 1 | Withdrawn | Disphar International B.V. | 2014-06-01 | 2016-12-02 | |
| Antidiabetic Effects on Intrahepatic Fat Liraglutide, Metformin, Gliclazide - Non-Alcoholic Fatty Liver Disease, Type2 Diabetes | Phase 4 | Completed | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 87 | 2014-05-01 | 2017-03-01 |
| Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial. Sitagliptin, Gliclazide, Sitagliptin matched placebo - Psoriasis, Type 2 Diabetes Mellitus | Phase 2 | Completed | University College Dublin | 20 | 2014-04-01 | 2020-05-14 |
| Incretin-based Drugs and the Risk of Heart Failure DPP-4 inhibitors, GLP-1 analogs, Insulins - Type 2 Diabetes Mellitus | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | 1499650 | 2014-03-01 | 2016-04-19 |
Showing 20 of 44. Sign in to see all of them.
Diabetes Mellitus, Type 2 (33) · Diabetes Mellitus (10) · Diabetic Nephropathies (2) · Insulin Resistance (2) · Angina Pectoris (1) · Atherosclerosis (1) · Bone Diseases, Metabolic (1) · Cardiovascular Diseases (1) · Cognitive Dysfunction (1) · Coronary Artery Disease (1) · Epilepsy (1) · Heart Failure (1) · Hypoglycemia (1) · Non-alcoholic Fatty Liver Disease (1) · Osteoporosis (1)
Canadian Network for Observational Drug Effect Studies, CNODES (3) · Merck Sharp & Dohme LLC (3) · Novartis Pharmaceuticals (3) · University of Dundee (3) · Centro de Diabetes Curitiba Ltda (2) · M.H.H. Kramer (2) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (2) · Ankara University (1) · Astellas Pharma Inc (1) · Bial - Portela C S.A. (1) · Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited (1) · Charles University, Czech Republic (1) · Chinese University of Hong Kong (1) · Disphar International B.V. (1) · Hospices Civils de Lyon (1)
United Kingdom (8) · China (7) · Germany (4) · Canada (3) · Brazil (2) · Egypt (2) · Hong Kong (2) · Japan (2) · Jordan (2) · Netherlands (2) · Singapore (2) · Switzerland (2) · Turkey (Türkiye) (2) · Bosnia and Herzegovina (1) · Czechia (1)
Ewan R Pearson (3) · Pierre Ernst, MD, MSc (3) · Andre GD Vianna, MD (2) · Abla Mohamed Ebeid, Ph D (1) · Aida Kulo Cesic, PhD (1) · Altug S Kesikli, MD. PhD. (1) · Andrew T Hattersley, FRCP, DM, BM (1) · Brian Kirby, MBBChBAOMD (1) · Brian Tomlinson (1) · Bruno Jolain (1) · Dalong Zhu, MD,PhD (1) · Jianping Weng, MD,PHD (1)
PMID 37435938, PMID 18502299, PMID 19221978, PMID 19705345, PMID 21537424, PMID 24920915, PMID 26625270, PMID 26888382, PMID 27007958, PMID 27479930, PMID 27502307, PMID 28271251, PMID 28515791, PMID 31606880, PMID 31816432, PMID 32200854, PMID 32516291, PMID 33205810, PMID 33693776, PMID 35221224, PMID 35322793, PMID 38770818, PMID 41619161, PMID 41665872
2015 (1)